HRP20241435T1 - Nova upotreba agonista angiotenzinskog ii receptora tipa 2 - Google Patents
Nova upotreba agonista angiotenzinskog ii receptora tipa 2 Download PDFInfo
- Publication number
- HRP20241435T1 HRP20241435T1 HRP20241435TT HRP20241435T HRP20241435T1 HR P20241435 T1 HRP20241435 T1 HR P20241435T1 HR P20241435T T HRP20241435T T HR P20241435TT HR P20241435 T HRP20241435 T HR P20241435T HR P20241435 T1 HRP20241435 T1 HR P20241435T1
- Authority
- HR
- Croatia
- Prior art keywords
- use according
- respiratory
- compound
- virus
- pharmaceutically acceptable
- Prior art date
Links
- 102000000469 Angiotensin II receptor type 2 Human genes 0.000 title 1
- 108050008993 Angiotensin II receptor type 2 Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 241000700605 Viruses Species 0.000 claims 9
- 230000000241 respiratory effect Effects 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000002345 respiratory system Anatomy 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000000451 tissue damage Effects 0.000 claims 4
- 231100000827 tissue damage Toxicity 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- -1 H2 receptor blockers Substances 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 241000712461 unidentified influenza virus Species 0.000 claims 2
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 241001678559 COVID-19 virus Species 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 108010005716 Interferon beta-1a Proteins 0.000 claims 1
- 102000003996 Interferon-beta Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000002588 alveolar type II cell Anatomy 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000000954 anitussive effect Effects 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 238000009175 antibody therapy Methods 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003434 antitussive agent Substances 0.000 claims 1
- 229940124584 antitussives Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960004461 interferon beta-1a Drugs 0.000 claims 1
- 229960001388 interferon-beta Drugs 0.000 claims 1
- 238000005399 mechanical ventilation Methods 0.000 claims 1
- 229960004584 methylprednisolone Drugs 0.000 claims 1
- 230000000510 mucolytic effect Effects 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 238000006213 oxygenation reaction Methods 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims 1
- 201000004193 respiratory failure Diseases 0.000 claims 1
- 159000000000 sodium salts Chemical group 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2004209.9A GB202004209D0 (en) | 2020-03-23 | 2020-03-23 | New use |
| GBGB2009574.1A GB202009574D0 (en) | 2020-06-23 | 2020-06-23 | New use |
| US17/113,616 US20210176086A1 (en) | 2019-12-09 | 2020-12-07 | Notification control device, notification control system, and notification control method |
| EP21715306.3A EP4125881B1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
| PCT/GB2021/050699 WO2021191592A1 (en) | 2020-03-23 | 2021-03-22 | New use of angiotensin ii type 2 receptor agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241435T1 true HRP20241435T1 (hr) | 2024-12-20 |
Family
ID=77747178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241435TT HRP20241435T1 (hr) | 2020-03-23 | 2021-03-22 | Nova upotreba agonista angiotenzinskog ii receptora tipa 2 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11123329B1 (https=) |
| EP (1) | EP4125881B1 (https=) |
| JP (1) | JP7671305B2 (https=) |
| CN (1) | CN115605201A (https=) |
| CA (1) | CA3176108A1 (https=) |
| ES (1) | ES2992423T3 (https=) |
| HR (1) | HRP20241435T1 (https=) |
| HU (1) | HUE068662T2 (https=) |
| PL (1) | PL4125881T3 (https=) |
| RS (1) | RS66072B1 (https=) |
| SM (1) | SMT202400427T1 (https=) |
| WO (1) | WO2021191592A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202004094D0 (en) * | 2020-03-20 | 2020-05-06 | Vicore Pharma Ab | New compounds and uses |
| US20220233480A1 (en) * | 2020-03-23 | 2022-07-28 | Vicore Pharma Ab | Use of angiotensin ii type 2 receptor agonist |
| AU2021258178A1 (en) * | 2020-04-22 | 2022-11-17 | Airway Therapeutics, Inc. | Use of surfactant protein D to treat viral infections |
| US20240408065A1 (en) * | 2021-09-30 | 2024-12-12 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Cyano compound, and preparation method therefor and use thereof |
| CN115583984A (zh) * | 2022-01-11 | 2023-01-10 | 嘉兴安谛康生物科技有限公司 | 氮杂螺类化合物及其制备方法、药物组合物和用途 |
| CN114948950A (zh) * | 2022-01-19 | 2022-08-30 | 广州谷森制药有限公司 | 一种药物组合物及其抗病毒用途 |
| WO2024153020A1 (zh) * | 2023-01-16 | 2024-07-25 | 海南先声药业有限公司 | 抗病毒药物组合物及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1529697B (zh) | 2001-05-31 | 2010-09-22 | 维科尔药物公司 | 用作血管紧张素ⅱ激动剂的三环化合物 |
| EP1723962A1 (en) | 2005-05-19 | 2006-11-22 | IMBA-Institut für Molekulare Biotechnologie GmbH | Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries |
| EP3265082A1 (en) | 2015-03-02 | 2018-01-10 | Vicore Pharma AB | Angiotensin ii receptor agonist for treating pulmonary fibrosis |
| GB201818164D0 (en) | 2018-11-07 | 2018-12-19 | Vicore Pharma Ab | New composition |
-
2020
- 2020-12-07 US US17/113,416 patent/US11123329B1/en active Active
-
2021
- 2021-03-22 EP EP21715306.3A patent/EP4125881B1/en active Active
- 2021-03-22 WO PCT/GB2021/050699 patent/WO2021191592A1/en not_active Ceased
- 2021-03-22 CA CA3176108A patent/CA3176108A1/en active Pending
- 2021-03-22 SM SM20240427T patent/SMT202400427T1/it unknown
- 2021-03-22 RS RS20241153A patent/RS66072B1/sr unknown
- 2021-03-22 PL PL21715306.3T patent/PL4125881T3/pl unknown
- 2021-03-22 HR HRP20241435TT patent/HRP20241435T1/hr unknown
- 2021-03-22 ES ES21715306T patent/ES2992423T3/es active Active
- 2021-03-22 JP JP2022557150A patent/JP7671305B2/ja active Active
- 2021-03-22 HU HUE21715306A patent/HUE068662T2/hu unknown
- 2021-03-22 CN CN202180035480.3A patent/CN115605201A/zh active Pending
- 2021-08-27 US US17/458,886 patent/US20210386712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2992423T3 (es) | 2024-12-12 |
| JP7671305B2 (ja) | 2025-05-01 |
| US11123329B1 (en) | 2021-09-21 |
| CN115605201A (zh) | 2023-01-13 |
| EP4125881A1 (en) | 2023-02-08 |
| JP2023520323A (ja) | 2023-05-17 |
| US20210386712A1 (en) | 2021-12-16 |
| EP4125881C0 (en) | 2024-07-24 |
| RS66072B1 (sr) | 2024-11-29 |
| CA3176108A1 (en) | 2021-09-30 |
| SMT202400427T1 (it) | 2024-11-15 |
| HUE068662T2 (hu) | 2025-01-28 |
| PL4125881T3 (pl) | 2024-12-02 |
| US20210290596A1 (en) | 2021-09-23 |
| WO2021191592A1 (en) | 2021-09-30 |
| EP4125881B1 (en) | 2024-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241435T1 (hr) | Nova upotreba agonista angiotenzinskog ii receptora tipa 2 | |
| JP2023520323A5 (https=) | ||
| AU631711B2 (en) | An aerosol preparation of glutathione and a method for augmenting glutathione level in lungs | |
| SI9200403B (en) | New combination of a bronchodilator and a steroidal antiinflammatory drug for treatment of respiratory disorders as well as its use and preparation thereof | |
| HRP20191257T1 (hr) | Farmaceutske formulacije koje sadrže 4-{(1r)-2-[(6-{2-[(2,6-diklorbenzil)oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenol | |
| RU2007119721A (ru) | Частицы для лечения легочной инфекции | |
| WO2011047065A1 (en) | Recombinant human cc10 protein for treatment of influenza | |
| CN112386595A (zh) | 一种治疗呼吸系统病毒性感染的药物组合物 | |
| WO2021203702A1 (zh) | 焦谷氨酸在制备预防和治疗新冠肺炎新型冠状病毒的药物中的应用 | |
| JP2025508656A5 (https=) | ||
| EP4232073B1 (en) | New dosage regimen for inhaled vasoactive intestinal polypeptide | |
| AU2009254262B2 (en) | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes | |
| US20030045577A1 (en) | Method for preventing infectious respiratory diseases | |
| JP2002348240A (ja) | 医薬組成物 | |
| WO2016036273A1 (ru) | Лекарственное средство для профилактики и лечения заболеваний дыхательных путей | |
| Waskin | Toxicology of antimicrobial aerosols: a review of aerosolized ribavirin and pentamidine | |
| US11724077B2 (en) | Therapeutic swabs for treating upper respiratory infections | |
| JPH09227373A (ja) | 抗インフルエンザウイルス剤 | |
| CN115884770A (zh) | 治疗冠状病毒感染的联用药物及治疗方法 | |
| Johnston | Cromolyns: treatment for the common cold? | |
| Haff et al. | The nasal decongestant action of aspirin in influenza infected ferrets | |
| EP2133089A1 (en) | Compositions for the treatment of disorders of the upper respiratory tract and influenza syndromes | |
| TR202100552A2 (tr) | Covid-19 ve di̇ğer vi̇ral akci̇ğer hastaliklarinin semptomlarinda ti̇treşi̇mli̇ elek teknoloji̇si̇ nebuli̇zatör i̇le anti̇koagülanlarin i̇nhale kullanilmasi | |
| WO2024019519A1 (ko) | iCP-NI를 포함하는 싸이토카인 폭풍 또는 염증성 질환의 치료 또는 예방용 약학적 조성물 | |
| AU605580B2 (en) | Aerosolization of protein therapeutic agent |